Zhengye Biotechnology-AZYBT
13F holders, Q1 2026 (March 31)8holders −3
0new positions
3sold out
$0.93avg. 13F price*
At the end of Q1 2026, 8 institutions reported holding Zhengye Biotechnology-A (ZYBT) in their 13F filings, down 3 from Q4 2025. 0 opened new positions and 3 sold out. The largest holders were XTX Topco Ltd ($41K), WINTON GROUP Ltd ($31K) and Geode Capital Management, LLC ($27K).
- Company
- Zhengye Biotechnology-A
- CUSIP
- G989MS101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $76K |
All 13F filers, Q4 2025 → Q1 2026: 3,552 shares bought and 113,194 shares sold, net −109,642 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| XTX Topco Ltd | 0.00% | Reduce -25.5% | 44,146 | $41K |
| WINTON GROUP Ltd | 0.00% | Reduce -47.3% | 33,389 | $31K |
| Geode Capital Management, LLC | 0.00% | No change | 29,068 | $27K |
| UBS Group AG | 0.00% | Reduce -11.8% | 8,036 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +122.6% | 4,912 | $5K |
| Royal Bank of Canada | 0.00% | Add +221.2% | 1,230 | $1K |
| Morgan Stanley | 0.00% | Reduce -83.8% | 261 | $244 |
| Caitong International Asset Management Co., Ltd | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is ZYBT's weight in each manager's 13F, not the share of Zhengye Biotechnology-A the manager owns.